跳至主要内容
临床试验/CTRI/2022/05/042586
CTRI/2022/05/042586尚未招募2 期

Role of Vitamin C supplement as an adjunct to tuberculosis treatment in new smear sputum positive pulmonary tuberculosis – An exploratory trial

ICMR National Institute for Research in Tuberculosis0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Adult patients aged between 18 – 60 years (both ages inclusive).
  • Patients should have at least two sputum smear samples positive for tubercle bacilli (at least 1+).
  • Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary tuberculosis (or with less than 7 days of ATT).
  • Sputum sensitive to INH and RIF
  • Willing for study procedures
  • Patients should be residing in or around clinical trial sites geographical location.
  • A chest X-ray picture which in the opinion of the Investigator is compatible with tuberculosis
  • Female participants of childbearing potential must have a negative urine pregnancy test and agree to use a highly effective method of birth control (i.e. tubal ligation, vaginal diaphragm, intrauterine device, condom or sponge with spermicide, oral contraceptives, contraceptive implant, combined hormonal patch, combined injectable contraceptive or depot-medroxyprogesterone acetate, partner(s) has had a vasectomy) throughout the treatment period in the trial.
  • Patient should express willingness to attend the treatment centre for supervised treatment
  • Patient should express willingness to give written informed consent prior to all trial-related procedures including HIV testing.
  • No history of intolerance, allergy or contraindication to any of the drugs to be administered

排除标准

  • TB Patients with body weight less than 30 kgs
  • Clinically significant evidence of extrapulmonary tuberculosis (miliary tuberculosis, abdominal tuberculosis, urogenital tuberculosis, osteoarthritic tuberculosis, tuberculous meningitis), as judged by the investigator.
  • Uncontrolled Diabetes Mellitus (Hb A1C > 8 %)
  • Patient sero-positive for HIV antibodies, serology tests positive for Hepatitis B surface antigen or Hepatitis C virus antibody
  • Pregnancy or lactating females
  • On treatment with immunosuppressive drugs
  • Glucose 6-phosphate dehydrogenase deficiency
  • Clinical and /social condition deemed unsuitable/ unsafe for participation in study
  • Evidence of clinically significant metabolic, respiratory ( other than TB) gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities/serious illness (other than the indication being studied).
  • Previous history of tuberculosis.
  • Known or suspected alcohol dependence within the past 6 months (audit score of 8 or more) or drug abuse, that is, in the opinion of the investigator, sufficient to compromise the safety or cooperation of the patient.
  • Patients with hepatic or renal disease as evidenced by clinical or biochemical abnormalities i.e., history of liver disease, current ALT > 2.5 times ULN or total bilirubin concentration >1.2 times ULN, Serum Creatinine >1.2 mg/dL, Blood Urea >43 mg/dL
  • Haemoglobin concentration <7.0 g/dL or platelet count <150,000/mm3, or white blood cell count <4500 cells/µL
  • Use of any therapeutic agents known to alter any major organ function (e.g., barbiturates, opiates, phenothiazines, cimetidine) within 30 days prior to dosing.

研究者

发起方
ICMR National Institute for Research in Tuberculosis

相似试验